Brief: Applied Molecular Transport Expands Clinical Pipeline And Announces First Subject Dosed In Phase 1A Trial Of Oral AMT-126

Applied Molecular Transport.

01/03/2021 14:10

March 1 (Reuters) - Applied Molecular Transport Inc.
 AMTI.O :
    * APPLIED MOLECULAR TRANSPORT EXPANDS CLINICAL PIPELINE AND
ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1A TRIAL OF ORAL AMT-126
    * APPLIED MOLECULAR TRANSPORT INC. - COMPLETE ORAL AMT-126
PHASE
1A/B DATA IN HEALTHY VOLUNTEERS AND PATIENTS ANTICIPATED IN 2022
    * APPLIED MOLECULAR TRANSPORT INC. - ON TRACK TO ANNOUNCE
ORAL
AMT-101 TOP-LINE DATA READOUTS FROM 4 PHASE 2 TRIALS BEGINNING
IN H2 OF 2021

Source text for Eikon:  ID:nGNXbztqSD 
Further company coverage:  AMTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))